Pharmanutra Resultados de beneficios anteriores

Pasado controles de criterios 6/6

Pharmanutra ha aumentado sus beneficios a una tasa media anual de 5.9%, mientras que los beneficios de la industria de Personal Products han experimentado un crecimiento de 3.8% anual. Los ingresos han ido creciendo a una tasa media de 16.7% al año. La rentabilidad financiera de Pharmanutra es de 27.6%, y sus márgenes netos son de 14.4%.

Información clave

5.9%

Tasa de crecimiento de los beneficios

4.5%

Tasa de crecimiento del BPA

Crecimiento de la industria Personal Products	13.6%
Tasa de crecimiento de los ingresos	16.7%
Rentabilidad financiera	27.6%
Margen neto	14.4%
Última actualización de beneficios	30 Sep 2024

Actualizaciones de resultados anteriores recientes

Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Mar 23

Recent updates

Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) Earnings

Sep 11

Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Mar 23

Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?

Mar 10

Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?

Feb 17

Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?

Feb 01

Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?

Jan 18

Is Pharmanutra (BIT:PHN) A Risky Investment?

Jan 04

Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return

Dec 22

Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?

Dec 08

Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?

Nov 23

Desglose de ingresos y gastos

Cómo gana y gasta dinero Pharmanutra. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

BIT:PHN Ingresos, gastos y beneficios (EUR Millions)
Fecha	Ingresos	Beneficios	Gastos G+A
30 Sep 24	113	16	26
30 Jun 24	108	14	24
31 Mar 24	101	11	23
31 Dec 23	101	13	23
30 Sep 23	95	12	21
30 Jun 23	93	14	20
31 Mar 23	88	16	18
31 Dec 22	83	15	17
30 Sep 22	79	16	15
30 Jun 22	76	15	14
31 Mar 22	73	15	13
31 Dec 21	68	14	12
30 Sep 21	65	14	12
30 Jun 21	60	11	11
31 Mar 21	57	14	10
31 Dec 20	57	14	10
30 Sep 20	58	14	10
30 Jun 20	58	14	10
31 Mar 20	55	9	10
31 Dec 19	54	8	9
30 Sep 19	49	8	8
30 Jun 19	50	9	7
31 Mar 19	48	9	8
31 Dec 18	47	9	8
30 Sep 18	44	8	8
30 Jun 18	41	7	7
31 Mar 18	40	6	7
31 Dec 17	38	6	6
30 Sep 17	37	5	6
30 Jun 17	35	5	5
31 Mar 17	34	4	5
31 Dec 16	33	4	5
31 Dec 15	26	3	5

Ingresos de calidad: PHN tiene ganancias de alta calidad.

Margen de beneficios creciente: Los actuales márgenes de beneficio (14.4%) de PHN son superiores a los del año pasado (12.6%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: Los beneficios de PHN han crecido un 5.9% al año en los últimos 5 años.

Acelerando crecimiento: El crecimiento de los beneficios de PHN en el último año (36.3%) supera su media de 5 años (5.9% al año).

Beneficios vs. Industria: El crecimiento de los beneficios de PHN en el último año (36.3%) superó al de la industria Personal Products 10.8%.

Pharmanutra Resultados de beneficios anteriores

Pasado controles de criterios 6/6

Información clave

Actualizaciones de resultados anteriores recientes

Third quarter 2024 earnings released

Second quarter 2024 earnings released: EPS: €0.67 (vs €0.19 in 2Q 2023)

First quarter 2024 earnings released: EPS: €0.27 (vs €0.56 in 1Q 2023)

Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Pharmanutra S.p.A. to Report Fiscal Year 2023 Results on Mar 15, 2024

Recent updates

Third quarter 2024 earnings released

Second quarter 2024 earnings released: EPS: €0.67 (vs €0.19 in 2Q 2023)

Investors Interested In Pharmanutra S.p.A.'s (BIT:PHN) Earnings

First quarter 2024 earnings released: EPS: €0.27 (vs €0.56 in 1Q 2023)

Upcoming dividend of €0.85 per share

Pharmanutra's (BIT:PHN) Shareholders Have More To Worry About Than Only Soft Earnings

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Pharmanutra S.p.A. to Report Fiscal Year 2023 Results on Mar 15, 2024

Third quarter 2023 earnings released: EPS: €0.26 (vs €0.48 in 3Q 2022)

Second quarter 2023 earnings released: EPS: €0.19 (vs €0.49 in 2Q 2022)

First quarter 2023 earnings released

Upcoming dividend of €0.80 per share at 1.6% yield

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Pharmanutra S.p.A. to Report Fiscal Year 2022 Results on Mar 16, 2023

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of Akern s.r.l. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Pharmanutra S.p.A. (BIT:PHN) completed the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri.

Pharmanutra S.p.A. (BIT:PHN) entered into a signing of the contract for the acquisition of 100% share capital of Akern - S.R.L. from Red Lions S.P.A., Liside S.r.l and Jacopo Talluri for €15 million.

These 4 Measures Indicate That Pharmanutra (BIT:PHN) Is Using Debt Safely

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Less than half of directors are independent

PharmaNutra S.P.A. Announces European Union Authorises Marketing of CFAs as Novel Food

Pharmanutra (BIT:PHN) Could Easily Take On More Debt

Third quarter 2021 earnings released: EPS €0.39 (vs €0.18 in 3Q 2020)

Capital Allocation Trends At Pharmanutra (BIT:PHN) Aren't Ideal

Investor sentiment improved over the past week

Price target increased to €59.33

Pharmanutra (BIT:PHN) Will Be Hoping To Turn Its Returns On Capital Around

Price target increased to €50.67

Investor sentiment improved over the past week

Price target increased to €45.00

Is Now The Time To Put Pharmanutra (BIT:PHN) On Your Watchlist?

Upcoming dividend of €0.67 per share

Returns On Capital Signal Tricky Times Ahead For Pharmanutra (BIT:PHN)

Full year 2020 earnings released: EPS €1.45 (vs €0.87 in FY 2019)

Are Strong Financial Prospects The Force That Is Driving The Momentum In Pharmanutra S.p.A.'s BIT:PHN) Stock?

Is There More To The Story Than Pharmanutra's (BIT:PHN) Earnings Growth?

Should You Be Adding Pharmanutra (BIT:PHN) To Your Watchlist Today?

Is Pharmanutra S.p.A. (BIT:PHN) A Smart Choice For Dividend Investors?

Is Pharmanutra (BIT:PHN) A Risky Investment?

Shareholders Of Pharmanutra (BIT:PHN) Must Be Happy With Their 220% Total Return

New 90-day high: €33.70

Do Insiders Own Lots Of Shares In Pharmanutra S.p.A. (BIT:PHN)?

Market bids up stock over the past week

Is Pharmanutra S.p.A.'s(BIT:PHN) Recent Stock Performance Tethered To Its Strong Fundamentals?

New 90-day high: €28.80

Third quarter 2020 earnings released: EPS €0.18

New 90-day high: €27.20

First half earnings released

First half earnings released

New 90-day low - €22.40

Desglose de ingresos y gastos

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Descubre empresas con buenos resultados en el pasado